Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival

Journal of Clinical Oncology

Volumn 27, Issue 7, 2009, Pages 1108-1115

  De Reyniès, Aurélien ^b   Assié, Guillaume ^b   Rickman, David S ^b   Tissier, Frédérique ^b   Groussin, Lionel ^b   René Corail, Fernande ^b   Dousset, Bertrand ^b   Bertagna, Xavier ^b   Clauser, Eric ^b   Bertherat, Jérôme ^a  

^a université Paris Cité   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUB1 RELATED PROTEIN;

ADRENAL CORTEX CARCINOMA; ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER SURVIVAL; COHORT ANALYSIS; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MICROARRAY ANALYSIS; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; VALIDATION PROCESS;

ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADULT; AGED; AGED, 80 AND OVER; CLUSTER ANALYSIS; DIAGNOSIS, DIFFERENTIAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 61449137784     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.5678     Document Type: Article

References (44)

1. Grumbach MM, Biller BM, Braunstein GD, et al: Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann Intern Med 138:424-429, 2003
2. Allolio B, Fassnacht M: Clinical review: Adre- nocortical carcinoma: Clinical update. J Clin Endocri- nol Metab 91:2027-2037, 2006
3. Luton JP, Cerdas S, Billaud L, et al: Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322:1 195-1201, 1990
4. Hamrahian AH, Ioachimescu AG, Remer EM, et al: Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab 90:871-877, 2005
5. Weiss LM, Medeiros LJ, Vickery AL Jr: Pathologic features of prognostic significance in adrenocor-tical carcinoma. Am J Surg Pathol 13:202-206, 1989
6. Schteingart DE, Doherty GM, Gauger PG, et al: Management of patients with adrenal cancer: Recommendations of an international consensus conference. Endocr Relat Cancer 12:667-680, 2005
7. Klibanski A, Stephen AE, Greene MF, et al: Case records of the Massachusetts General Hospital. Case 36-2006. A 35-year-old pregnant woman with new hypertension. N Engl J Med 355:2237-2245, 2006
8. Pohlink C, Tannapfe A, Eichfeld U, et al: Does tumor heterogeneity limit the use of the Weiss criteria in the evaluation of adrenocortical tumors? J Endocrinol Invest 27:565-569, 2004
9. Macfarlane DA: Cancer of the adrenal cortex; the natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl 23:155-186, 1958
10. Abiven G, Coste J, Groussin L, et al: Clinical and biological features in the prognosis of adreno-cortical cancer: Poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 91:2650-2655, 2006
11. Icard P, Goudet P, Charpenay C, et al: Adre- nocortical carcinomas: Surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 25:891-897, 2001
12. Stojadinovic A, Ghossein RA, Hoos A, et al: Adrenocortical carcinoma: Clinical, morphologic, and molecular characterization. J Clin Oncol 20:941-950, 2002
13. Assie G, Antoni G, Tissier F, et al: Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 92:148-154, 2007
14. Terzolo M, Angeli A, Fassnacht M, et al: Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356:2372-2380, 2007
15. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004
16. Wang Y, Klijn JG, Zhang Y, et al: Gene- expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671-679, 2005
17. Chen HY, Yu SL, Chen CH, et al: A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 356:11-20, 2007
18. Potti A, Mukherjee S, Petersen R, et al: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 355:570-580, 2006
19. Pollack JR: A perspective on DNA microarrays in pathology research and practice. Am J Pathol 171: 375-385, 2007
20. de Fraipont F, El Atifi M, Cherradi N, et al: Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab 90:1819-1829, 2005
21. Giordano TJ, Thomas DG, Kuick R, et al: Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol 162:521-531, 2003
22. Bertherat J, Contesse V, Louiset E, et al: In vivo and in vitro screening for illegitimate receptors in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing's syndrome: Identification of two cases of gonadotropin/gastric inhibitory polypeptide-dependent hypercortisolism. J Clin Endocrinol Metab 90:1302-1310, 2005
23. Luton JP, Martinez M, Coste J, et al: Outcome in patients with adrenal incidentaloma selected for surgery: An analysis of 88 cases investigated in a single clinical center. Eur J Endo- crinol 143:111-117, 2000
24. Sullivan M, Boileau M, Hodges CV: Adrenal cortical carcinoma. J Urol 120:660-665, 1978
25. Weiss LM: Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 8:163-169, 1984
26. Gicquel C, Bertagna X, Gaston V, et al: Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 61:6762-6767, 2001
27. Irizarry RA, Bolstad BM, Collin F, et al: Summaries of Affymetrix GeneChip probe level data. Nucleic Acid Res 31:e15, 2003
28. Lamant L, de Reynies A, Duplantier MM, et al: Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood 109:2156-2164, 2007
29. Libe R, Fratticci A, Bertherat J: Adrenocortical cancer: Pathophysiology and clinical management. Endocr Relat Cancer 14:13-28, 2007
30. Bertherat J, Groussin L, Bertagna X: Mechanisms of disease: Adrenocortical tumors-molecular advances and clinical perspectives. Nat Clin Pract Endocrinol Metab 2:632-641, 2006
31. Slater EP, Diehl SM, Langer P, et al: Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. Eur J Endocrinol 154: 587-598, 2006
32. Velazquez-Fernandez D, Laurell C, Geli J, et al: Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery 138:1087-1094, 2005
33. West AN, Neale GA, Pounds S, et al: Gene expression profiling of childhood adrenocortical tumors. Cancer Res 67:600-608, 2007
34. Wong J, Fang G: HURP controls spindle dynamics to promote proper interkinetochore tension and efficient kinetochore capture. J Cell Biol 173: 879-891, 2006
35. Chiu AW, Huang YL, Huan SK, et al: Potential molecular marker for detecting transitional cell carcinoma. Urology 60:181-185, 2002
36. Tsou AP, Yang CW, Huang CY, et al: Identification of a novel cell cycle regulated gene, HURP, overexpressed in human hepatocellular carcinoma. Oncogene 22:298-307, 2003
37. Gudmundsson KO, Thorsteinsson L, Sigurjon- sson OE, et al: Gene expression analysis of hema-topoietic progenitor cells identifies Dlg7 as a potential stem cell gene. Stem Cells 25:1498-1506, 2007
38. Unoki M, Nakamura Y: Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 20:4457-4465, 2001
39. Chan GK, Jablonski SA, Sudakin V, et al: Human BUBR1 is a mitotic checkpoint kinase that monitors CENP-E functions at kinetochores and binds the cyclosome/APC. J Cell Biol 146:941-954, 1999
40. Wang Q, Liu T, Fang Y, et al: BUBR1 deficiency results in abnormal megakaryopoiesis. Blood 103:1278-1285, 2004
41. Rao CV, Yang YM, Swamy MV, et al: Colonic tumorigenesis in BubR1 +/-ApcMin/+ compound mutant mice is linked to premature separation of sister chromatids and enhanced genomic instability. Proc Natl Acad SciUSA 102:4365-4370, 2005
42. Kirschner LS: Emerging treatment strategies for adrenocortical carcinoma: A new hope. J Clin Endocrinol Metab 91:14-21, 2006
43. Schteingart DE: Adjuvant mitotane therapy of adrenal cancer - use and controversy. N Engl J Med 356:2415-2418, 2007
44. Bertherat J, Coste J, Bertagna X: Adjuvant mitotane in adrenocortical carcinoma. N Engl J Med 357:1256-1257